Search Results
Mar 16, 2026, 13:57 ET Egret Therapeutics Signs Memorandum of Understanding with Genexine Toward Full Ownership of Lead PD-1 Agonist Asset GX-P1 (EGT-101)
hyFc technology platform designed to enhance the half-life and efficacy of therapeutic proteins. In addition, Genexine is advancing a next-generation mRNA-based bioPROTAC platform for targeted protein degradation, designed to selectively eliminate disease-causing intracellular proteins, including key oncogenic
More news about: Turret Capital Management
Mar 16, 2026, 08:00 ET Argo Biopharma Receives FDA Fast Track Designation for BW-20805, an Investigational siRNA Therapy for the Treatment of HAE
prophylactic treatments are limited by frequent dosing, highlighting the need for long-acting, preventive therapies. BW-20805 targets human hepatic PKK mRNA to inhibit PKK gene expression, offering the potential for effective prevention of HAE attacks with a significant and longer-lasting therapeutic effect.About
More news about: Argo Biopharmaceutical Co., Ltd
Mar 16, 2026, 05:54 ET Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026 and Hold Online Earnings Call
omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster
More news about: Everest Medicines
Mar 15, 2026, 22:05 ET Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance
multi-specific antibody platform, Dual-Shield Antibody-Drug Conjugates (ADCs), Dual-Lock T-cell engager (TCE), Tissue-Smart siRNA, Cell Therapies, and Flex-Nano mRNA platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has
More news about: Akeso, Inc.
Mar 12, 2026, 08:53 ET CityUHK researchers unveil the mystery of "Asian Flush" mechanism, pioneering new directions in precision treatment for heart attacks
of Circulation. Entitled "Selective mRNA Translation: A New Player in Ferroptosis After Myocardial Infarction", the piece is authored by Professor Yi Zhu, a renowned scientist in
More news about: City University of Hong Kong (CityUHK)
Mar 12, 2026, 08:33 ET CityUHK researchers unveil the mystery of "Asian Flush" mechanism, pioneering new directions in precision treatment for heart attacks
of Circulation. Entitled "Selective mRNA Translation: A New Player in Ferroptosis After Myocardial Infarction", the piece is authored by Professor Yi Zhu, a renowned scientist in
More news about: City University of Hong Kong (CityUHK)
Mar 12, 2026, 03:01 ET GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub
strongest life science ecosystems, the Delft site provides end-to-end mRNA workflow capabilities, including:Gene design and synthesisVector engineeringIVT mRNA productionProprietary GenCap™ mRNA capping technologyUTR optimization and formulation supportThe
More news about: GenScript Biotech Corporation
Mar 12, 2026, 02:49 ET GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub
strongest life science ecosystems, the Delft site provides end-to-end mRNA workflow capabilities, including:Gene design and synthesisVector engineeringIVT mRNA productionProprietary GenCap™ mRNA capping technologyUTR optimization and formulation supportThe
More news about: GenScript Biotech Corporation
Mar 11, 2026, 12:23 ET Full Circles Therapeutics Highlights Circular Single-Stranded DNA Platform Enabling Immune-Evasive Genome Writing in Nature Study
cells."Circular single-stranded DNA provides a fundamentally different genetic payload compared with conventional double-stranded DNA or transient mRNA approaches," said Howard Wu, PhD, Co-founder, CEO and Chief Scientific Officer of Full Circles Therapeutics. "By enabling kilobase-scale gene writing
More news about: Full Circles Therapeutics
Mar 11, 2026, 04:00 ET ARTHEx Biotech Granted FDA Fast Track Designation for ATX-01 for the Treatment of Myotonic Dystrophy Type 1 (DM1)
activity occurs through two complementary mechanisms: first, upregulation of miR-23b reduces MBNL protein expression; and second, expanded toxic DMPK mRNA sequesters MBNL proteins within the nucleus. The resulting depletion of available MBNL proteins leads to widespread RNA mis-splicing (spliceopathy),
More news about: ARTHEx Biotech
Mar 10, 2026, 12:35 ET AcuraStem Awarded Target ALS Grant to Advance Therapeutics Targeting a Core Driver of ALS
The Target ALS Drug Discovery Consortium award will support mechanistic and translational studies of SYF2, a pre-mRNA splicing factor whose modulation has been shown in preclinical models to restore normal TDP-43 activity and protect motor neurons. Because TDP-43 dysfunction
More news about: AcuraStem - Patient-Based Therapeutics
Mar 10, 2026, 07:00 ET Samsung Biologics Announces Collaboration with Lilly to Establish New Gateway Labs Site in Korea
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeuticsBy implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced
More news about: Samsung Biologics
Mar 10, 2026, 06:16 ET Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026
omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster
More news about: Everest Medicines
Mar 09, 2026, 06:00 ET IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
MTAP-deleted versus MTAP wild type HCT116 isogenic cell lines. In addition, IDE892 inhibited the arginine dimethylation of a key PRMT5 substrate involved in mRNA splicing, spliceosome protein SmB (SmB-SDMA), with pico-molar potency in MTAP-deleted cell lines with greater than 100-fold potency differential versus
More news about: IDEAYA Biosciences, Inc.
Mar 05, 2026, 10:16 ET Lipid Nanoparticles Market to Reach $3.1 Billion, Globally, by 2033 at 13.1% CAGR: Allied Market Research
The lipid nanoparticles market growth is driven by rising demand for advanced drug delivery systems, increasing adoption of mRNA-based therapeutics and vaccines, and continuous innovations in nanomedicine. In addition, expanding pharmaceutical and biotechnology research, growth of gene therapy
More news about: Allied Market Research
Mar 05, 2026, 08:00 ET Therna Announces Collaboration with Charles River to Advance Single-Patient Personalized RNA Therapeutics
AI-enabled RNA design platform, the mRNA therapeutic candidate for lung fibrosis was generated in just three days and its properties were validated in the laboratory in less than three months. In addition to speed, Therna's AI platform enabled the creation of an mRNA candidate with potential enhanced durability,
More news about: Therna Biosciences
Mar 04, 2026, 21:26 ET Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results
robust R&D innovation ecosystem centered on its proprietary Tetrabody bispecific antibody platform, ADC (Antibody-Drug Conjugate) technologies, siRNA/mRNA modalities, and cell therapies. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization
More news about: Akeso, Inc.
Mar 04, 2026, 08:52 ET Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
robust R&D innovation ecosystem centered on its proprietary Tetrabody bispecific antibody platform, ADC (Antibody-Drug Conjugate) technologies, siRNA/mRNA modalities, and cell therapies. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization
More news about: Akeso, Inc.
Mar 04, 2026, 08:31 ET Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
below have shown success in rare cancers Potent gene-level target suppression: HT-KIT achieved >80% reduction of KIT mRNA/protein across in-vitro systems and in vivo models of systemic mastocytosis and GIST.Favorable tolerability in early studies:
More news about: Hoth Therapeutics, Inc.
Mar 04, 2026, 08:05 ET INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
robust R&D innovation ecosystem centered on its proprietary Tetrabody bispecific antibody platform, ADC (Antibody-Drug Conjugate) technologies, siRNA/mRNA modalities, and cell therapies. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization
More news about: INOVIO Pharmaceuticals, Inc.
Mar 04, 2026, 08:00 ET Minaris Launches AgentSCREEN Adventitious Virus Detection by NGS to Simplify Viral Safety Testing for Cell Banks and Cell-Based Samples
AgentSCREEN is a transcriptomic NGS approach with a predictable 28-day turnaround time. The assay examines all messenger RNA (mRNA) in a cell bank sample for the presence of viral RNA transcripts and is designed to detect active viral infections from RNA and DNA viruses. A custom
More news about: Minaris Advanced Therapies
Mar 04, 2026, 07:00 ET HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at 15th European Lupus Meeting
as compared to key benchmarks.In an in vivo mouse model, HotSpot's IRF5 inhibitors demonstrated dose-dependent inhibition of cytokines and mRNA response, as well as dose-dependent down-regulation of interferon and IRF5-driven gene signatures, confirming pathway-level modulation in this model.About
More news about: HotSpot Therapeutics
Mar 02, 2026, 16:19 ET Skyhawk gibt bekannt, dass die australische Arzneimittelbehörde festgestellt hat, dass SKY-0515 zur Behandlung der Huntington-Krankheit die Zulassungskriterien für den vorläufigen Zulassungsweg erfüllt
eine hohe Dosis von SKY-0515 in verblindeter Weise erhalten. Zu den Zielen der Studie gehört die Untersuchung des mutierten HTT-Proteins und der PMS1-mRNA. Die ersten Patienten wurden in Teil C von SKY-0515 im Januar 2025 behandelt. Die Rekrutierung für die Phase 1C der SKY-0515-Studie ist nun abgeschlossen
More news about: Skyhawk Therapeutics
Mar 02, 2026, 10:31 ET Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
participants receive either a low or high dose of SKY-0515 in a blinded fashion. The objectives of the study include evaluating mutant HTT protein and PMS1 mRNA. The first patients were dosed in SKY-0515's Part C in January 2025. Enrollment in Phase 1C of the SKY-0515 trial is now complete and the trial is ongoing.About
More news about: Skyhawk Therapeutics
Mar 02, 2026, 10:22 ET Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
participants receive either a low or high dose of SKY-0515 in a blinded fashion. The objectives of the study include evaluating mutant HTT protein and PMS1 mRNA. The first patients were dosed in SKY-0515's Part C in January 2025. Enrollment in Phase 1C of the SKY-0515 trial is now complete and the trial is ongoing.About
More news about: Skyhawk Therapeutics